Researchers address drug-related toxicity in chemotherapy and explore alternatives from traditional Chinese medicine to treat diabetic neuropathy.
Inflammatory bowel disease (IBD) is a common chronic gastrointestinal disorder and current treatment strategies can cause adverse effects. Thus, there is a need to identify alternative compounds to treat IBD. Similarly, the dose-related toxicity and efficacy of anticancer drugs must be monitored accurately to improve the treatment outcomes. Moreover, over the years, plant-based therapeutic compounds and traditional Chinese medicine formulae have gained attention for their enhanced healing effects. Volume 14, Issue 2 of the Journal of Pharmaceutical Analysis (JPA), published in February 2024, addresses these issues in three different studies, respectively.
The first study, published in Volume 14, Issue 2 of JPA, identified and extracted a plant-based, acidic polysaccharide named SUSP-4 from the herb Selaginella uncinata (Desv.) Spring. This phytocompound significantly improved the symptoms of IBD such as low body weight and high disease activity index during animal experiments. It inhibited the immune response of macrophage activation by altering the chemokine levels in treated animals and ultimately affected the thiamine metabolic pathway and protected against IBD. The corresponding author, Dr. Jinyong Peng states, „IBD reduces the level of vitamin B1 (thiamine), which itself has an inhibitory effect on inflammation, so a moderate supplementation of vitamin B1 may go a long way towards preventing IBD in people.“
https://www.sciencedirect.com/science/article/pii/S2095177923001879?via%3Dihub
Entdecke mehr von LabNews
Melde dich für ein Abonnement an, um die neuesten Beiträge per E-Mail zu erhalten.
